October 07, 2020
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
Media
October 01, 2020
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
October 01, 2020
Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
September 30, 2020
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
September 29, 2020
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
September 29, 2020
Fusion Pharmaceuticals Appoints Maria Stahl As Chief Legal Officer
September 28, 2020
GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology
September 25, 2020
Invitation – Orexo Digital Therapeutics business update October 1
September 25, 2020
Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue
September 23, 2020
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease